Tissue engineered myoblast sheets improved cardiac function sufficiently to discontinue LVAS in a patient with DCM: report of a case.
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by progressive heart failure, and is a leading cause of mortality and morbidity. Recently, cellular therapy for end-stage heart failure has been emerging. We herein report a 56-year-old male who received a transplant of autologous myoblast sheets manufactured in temperature-responsive culture dishes. His clinical condition improved markedly, leaving him without any arrhythmia and able to discontinue using a left ventricular assist system and avoid cardiac transplantation. These findings suggest that cellular therapy using myoblast sheets is a promising new strategy for treating patients with end-stage DCM. This method might be an effective alternative to heart transplantation in the near future.
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan. sawa@surg1.med.osaka-u.ac.jp
Yoshiki
Y
Sawa
Shigeru
S
Miyagawa
Taichi
T
Sakaguchi
Tomoyuki
T
Fujita
Akifumi
A
Matsuyama
Atsuhiro
A
Saito
Tatsuya
T
Shimizu
Teruo
T
Okano
D002311:Cardiomyopathy, Dilated / Q000503:physiopathology / Q000628:therapy*; D017690:Cell Transplantation / Q000295:instrumentation*; D002478:Cells, Cultured; D005500:Follow-Up Studies; D006353:Heart-Assist Devices; D006801:Humans; D008297:Male; D008875:Middle Aged; D032448:Myoblasts, Skeletal / Q000637:transplantation*; D013318:Stroke Volume / Q000502:physiology*; D023822:Tissue Engineering; D014182:Transplantation, Autologous; D016276:Ventricular Function / Q000502:physiology*